- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03621787
Assessing the Safety and Efficacy of a Novel Subcutaneous Implant Insertion Device on Healthy Adults
Assessing the Safety and Efficacy of the SubQ Assist Implant Insertion Device
The investigators have created a device designed to make it easier to insert pharmaceutical implants under the skin. The device uses a blood pressure cuff to hold the skin on a person's arm in place while a mechanical guide places implants underneath the skin. This device may prevent implants from being embedded too deeply.
The investigators are performing this study to determine the safety and efficacy of the device for use in adult women. The study will determine if the implants are placed accurately under the skin (in the sub-dermal layer). It will also assess if the device causes any discomfort or last pain from use.
Panoramica dello studio
Descrizione dettagliata
Subcutaneous contraceptive implants are one of the preferred methods of long-term contraception by the World health Organization and ministries of health in low- and middle-income countries. These implants offer between three and five years of protection (allowing women to safely space pregnancies and thereby reduce maternal and infant mortality), are 99.95% efficacious, allow women to return to fertility quickly when removed, requires no daily/monthly effort on the part of the woman, and cause minimal side effects in comparison to other methods. However, availability of contraceptive implants in rural areas is limited due to the skill necessary to administer them safely and accurately.
The investigators have created a device designed to make it easier to insert pharmaceutical implants under the skin. The device uses a blood pressure cuff to hold the skin on a person's arm in place while a mechanical guide places implants underneath the skin. This device is designed to prevent implants from being embedded too deeply.
In this trial, the investigators will use the implant insertion device with a placebo sub-cutaneous implant. Implants will be inserted with the device and the accuracy of the placement will be assessed through palpation and ultrasound depth measurements. This data will allow the investigators to assess whether the device ensures accurate insertions of sub-cutaneous implants.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- University of Michigan
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy adult subjects aged 18 to 49
- Ability to understand study procedure and informed consent document
Exclusion Criteria:
- Patients with a history of keloid scarring
- Pregnancy
- Any rashes or skin conditions around the insertion site
- Known silicone allergies
- Known allergy to lidocaine
- History of bleeding disorders or abnormal bleeding
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Single arm study: implant insertion
Participants in trial will be within a single study arm.
All participants will have a placebo subcutaneous implant inserted with the device being studied.
The implant accuracy will be assess through palpation and ultrasound depth measurements.
The implant will then be removed.
Safety will be assessed by measuring bruising and bleeding.
A follow-up questionnaire will assess bruising and infection risk.
A final visit will assess bruising and infection risk by a physician.
|
Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Implant Depth: Distal End
Lasso di tempo: Up to 60 minutes after insertion
|
Depth of distal end of implant beneath the skin after insertion.
Measured via high frequency ultrasound with linear probe.
Measured in centimeters below skin surface.
Measurements will be aggregated via mean and standard deviation.
|
Up to 60 minutes after insertion
|
Implant Depth: Proximal End
Lasso di tempo: Up to 60 minutes after insertion
|
Depth of distal end of implant beneath the skin after insertion.
Measured via high frequency ultrasound with linear probe.
Measured in centimeters below skin surface.
Measurements will be aggregated via mean and standard deviation.
|
Up to 60 minutes after insertion
|
Implant Palpability
Lasso di tempo: Up to 15 minutes after insertion
|
A binary (yes/no) assessment of whether the implant is palpable by a physician under the skin after insertion.
Measurements will be aggregated based on percent of implants that are palpable.
|
Up to 15 minutes after insertion
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants With Bruising
Lasso di tempo: Up to 15 minutes after insertion.
|
Bruising may occur from inflation of the blood pressure cuff over the device being studied.
A binary assessment of bruising (yes/no) will be assessed by the physician after insertion.
|
Up to 15 minutes after insertion.
|
Presence of Bruising
Lasso di tempo: 7 to 14 days after insertion
|
Bruising may occur from inflation of the blood pressure cuff over the device being studied.
Bruising will be assessed by the participant in a survey (binary yes/no indication of bruising around insertion site).
|
7 to 14 days after insertion
|
Number of Participants With More Bleeding Than Typical
Lasso di tempo: Up to 10 minutes after insertion
|
Bleeding from insertion will be assessed by the physician who has extensive training with implant insertions.
The number of participants with more bleeding than is typically associated with insertion will be measured.
|
Up to 10 minutes after insertion
|
Number of Participants With Signs of Infection
Lasso di tempo: 7 to 10 days after insertion
|
Infection will be assessed during the follow-up questionnaire. A binary assessment (yes/no) of the following will be assessed by the participant. 1) Is there currently any fluid draining from the incision? 2) Is there currently any redness or swelling of the insertion site? 3) Is there currently any bleeding from the insertion site? Participants who answer "Yes" to all three questions are deemed to have shown signs of infection. |
7 to 10 days after insertion
|
Number of Participants With Signs of Infection
Lasso di tempo: 21 to 28 days after insertion
|
A follow-up appointment with all participants was conducted by the physician who administered the implant. A binary assessment (yes/no) of the following will be assessed for each participant by the physician. 1) Is there currently any fluid draining from the incision? 2) Is there currently any redness or swelling of the insertion site? 3) Is there currently any bleeding from the insertion site? If the physician answers "Yes" to all three questions, the participant is deemed to have shown signs of infection. |
21 to 28 days after insertion
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Kathleen H Sienko, PhD, Associate Professor
- Investigatore principale: Carrie L Bell, MD, Assistant Professor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- SubQAssist0001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Implant insertion device
-
Apreo Health, Inc.ReclutamentoEnfisema o BPCORegno Unito, Austria, Olanda
-
Apreo Health, Inc.ReclutamentoEnfisema o BPCOAustralia
-
Zimmer BiometRitiratoMalattia degenerativa del discoStati Uniti
-
Massachusetts General HospitalSconosciutoCancro al seno | Chirurgia | Articolo chirurgico, trattenuto
-
The Royal College of Surgeons of EdinburghReclutamentoPerdita ossea alveolareEgitto, Germania
-
Farhan KarimDePuy SynthesReclutamentoMalattia degenerativa del disco | Stenosi spinale lombare | Spondilolistesi lombare | Stenosi foraminaleStati Uniti
-
Guy's and St Thomas' NHS Foundation TrustSconosciuto
-
LifeCellTerminatoMastectomia e ricostruzione mammariaFrancia, Germania, Regno Unito
-
Advanced BionicsCompletatoMalattie otorinolaringoiatriche | Malattie dell'orecchio | Perdita dell'udito | Disturbi dell'uditoStati Uniti
-
Ideal Implant IncorporatedCompletato